SuzanneElizabethEaton-JonesMD

PubMed

• 29 citations
  Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.
  Kathleen N. Moore, Setsuko K. Chambers, Erika Hamilton, Lee-may Chen, Amit M. Oza, Sharad A. Ghamande, Gottfried E. Konecny, Steven C. Plaxe, Daniel Lewis Spitz, Jill ...> ;Clinical Cancer Research. 2021 Oct 13
• 10 citations
  A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
  Kathleen N. Moore, David S. Hong, Manish R. Patel, Shubham Pant, Susanna Varkey Ulahannan, Suzanne F. Jones, Funda Meric-Bernstam, Judy S. Wang, Raid Aljumaily, Erika ...> ;Targeted Oncology. 2021 Sep 1
• 14 citations
  Modernizing clinical trial eligibility criteria: Recommendations of the ASCO-friends of cancer research laboratory reference ranges and testing intervals work group
  Alexander I. Spira, Mark Stewart, Suzanne F. Jones, Elaine Chang, Anitra Fielding, Nicole Richie, Laura S. Wood, Michael A. Thompson, Lee W. Jones, Abhilasha Nair, Bra...> ;Clinical Cancer Research. 2021 May 1
• 18 citations
  Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
  David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna Varkey Ulahannan, Suzanne F. Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding...> ;Clinical Cancer Research. 2021 Jan 25
• 4 citations
  Molecular Profiling in Drug Development: Paving a Way Forward.
  Suzanne F. Jones, Andrew J. McKenzie> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2020 May 28
• 53 citations
  Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
  Geoffrey I. Shapiro, Patricia LoRusso, E. L. Kwak, Susan Pandya, Charles M. Rudin, Carla Kurkjian, James M. Cleary, Mary Jo Pilat, Suzanne F. Jones, Alex de Crespigny,...> ;Investigational New Drugs. 2020 Apr 1
• 23 citations
  A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squam...
  David R. Spigel, Dianna Shipley, David M. Waterhouse, Suzanne F. Jones, Patrick J. Ward, Kent C. Shih, Brian Hemphill, Michael McCleod, Robert C. Whorf, Ray D. Page, J...> ;The Oncologist. 2019 Dec 1
• Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
  Huali Wu, Jeffrey R. Infante, Vicki L. Keedy, Suzanne F. Jones, Emily Chan, Johanna C. Bendell, Wooin Lee, Whitney P Kirschbrown, Beth A. Zamboni, Satoshi Ikeda, Hiros...> ;International Journal of Nanomedicine. 2019 Jul 24
• 22 citations
  Should next-generation sequencing tests be performed on all cancer patients?
  Andrew J. McKenzie, Holli H. Dilks, Suzanne F. Jones, Howard A. Burris> ;Expert Review of Molecular Diagnostics. 2019 Jan 9
• 51 citations
  Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
  David S. Hong, Kathleen N. Moore, Manish R. Patel, Stefan C. Grant, Howard A. Burris, William N. William, Suzanne F. Jones, Funda Meric-Bernstam, Jeffrey R. Infante, L...> ;Clinical Cancer Research. 2018 Apr 11
• 33 citations
  TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
  Howard A. Burris, Carla Kurkjian, Lowell L. Hart, Shubham Pant, Patrick Murphy, Suzanne F. Jones, Rachel Neuwirth, Chirag Patel, F. Zohren, J. R. Infante> ;Cancer Chemotherapy and Pharmacology. 2017 Jun 10
• 69 citations
  A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
  Johanna C. Bendell, Milind Javle, Tanios Bekaii-Saab, Richard S. Finn, Zev A. Wainberg, Daniel A. Laheru, Colin D. Weekes, Benjamin R. Tan, Gazala Khan, Mark M. Zalups...> ;British Journal of Cancer. 2017 Feb 28
• 87 citations
  Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with ex...
  Howard A. Burris, Suzanne Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Danie...> ;ESMO Open. 2016 Dec 1
• 109 citations
  Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
  David S. Hong, Jeffrey R. Infante, Filip Janku, Suzanne F. Jones, Ly M. Nguyen, Howard A. Burris, Aung Naing, Todd M. Bauer, Sarina Anne Piha-Paul, Faye M. Johnson, Ra...> ;Journal of Clinical Oncology. 2016 Sep 27
• 479 citations
  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
  Jeffrey Wallin, Johanna C. Bendell, Roel Funke, Mario Sznol, Konstanty Korski, Suzanne F. Jones, Genevive Hernandez, James W. Mier, Xian He, F. Stephen Hodi, Mitchell ...> ;Nature Communications. 2016 Aug 30
• 17 citations
  A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
  Howard A. Burris, Jeffrey R. Infante, F. Anthony Greco, Dana S. Thompson, John H. Barton, Johanna C. Bendell, Yoshihiro Nambu, Noriko Watanabe, Suzanne F. Jones> ;Cancer Chemotherapy and Pharmacology. 2016 Apr 9
• 55 citations
  A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
  Shubham Pant, Suzanne F. Jones, Carla Kurkjian, Jeffrey R. Infante, Kathleen N. Moore, Howard A. Burris, D.S. McMeekin, Karim A. Benhadji, Bharvin K. R. Patel, Martin ...> ;European Journal of Cancer. 2016 Mar 1
• 7 citations
  Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
  Eric Laille, Manish Patel, Suzanne F. Jones, Howard A. Burris, Jeffrey R. Infante, Charlotte Lemech, Liangang Liu, Hendrik-Tobias Arkenau> ;Journal of Clinical Pharmacology. 2015 Dec 1
• 175 citations
  Molecular Pathways: Fatty Acid Synthase
  Suzanne F. Jones, Jeffrey R. Infante> ;Clinical Cancer Research. 2015 Oct 30
• 10 citations
  A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
  Johanna C. Bendell, Suzanne F. Jones, Lowell L. Hart, Shubham Pant, Adil Moyhuddin, Cassie M. Lane, Chris Earwood, Patrick Murphy, Jeffrey Patton, William Charles Penl...> ;Cancer Investigation. 2015 Oct 13
• 61 citations
  A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patient...
  Johanna C. Bendell, Robin Kate Kelley, Kent C. Shih, Jennifer A. Grabowsky, Emily K. Bergsland, Suzanne F. Jones, Thomas Martin, Jeffrey R. Infante, Paul S. Mischel, T...> ;Cancer. 2015 Oct 1
• 51 citations
  A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administere...
  Jhanelle E. Gray, Jeffrey R. Infante, Les H. Brail, George R. Simon, Jennifer F. Cooksey, Suzanne F. Jones, Daphne L. Farrington, Adeline Yeo, Kimberley Jackson, Kay H...> ;Investigational New Drugs. 2015 Sep 25
• 102 citations
  A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
  Suzanne F. Jones, Lillian L. Siu, Johanna C. Bendell, James M. Cleary, Albiruni Ryan Abdul Razak, Jeffrey R. Infante, Shuchi Sumant Pandya, Philippe L. Bedard, Kristen...> ;Investigational New Drugs. 2015 Sep 4
• 26 citations
  Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
  Philip T. Sager, Barbara Balser, Julie A. Wolfson, Jean Nichols, Richard Pilot, Suzanne F. Jones, Howard A. Burris> ;Cancer Medicine. 2015 Aug 1
• 9 citations
  Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors
  Donna S. Cox, Alicia Allred, YanYan Zhou, Jeffrey R. Infante, Michael S. Gordon, Johanna C. Bendell, Suzanne F. Jones, Howard A. Burris, Keith W. Orford> ;Clinical Pharmacology in Drug Development. 2015 Jul 1
• Join now to see all